A Reversal for Altimmune, Inc. (ALT) Is Not Near. The Stock Reaches 52 Week Low Today

April 21, 2018 - By Richard Conner

The stock of Altimmune, Inc. (NASDAQ:ALT) hit a new 52-week low and has $0.65 target or 8.00 % below today’s $0.71 share price. The 6 months bearish chart indicates high risk for the $12.82 million company. The 1-year low was reported on Apr, 21 by Barchart.com. If the $0.65 price target is reached, the company will be worth $1.03M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 6.47% or $0.049 during the last trading session, reaching $0.708. About 424,950 shares traded or 35.93% up from the average. Altimmune, Inc. (NASDAQ:ALT) has declined 84.57% since April 21, 2017 and is downtrending. It has underperformed by 96.12% the S&P500.

Analysts await Altimmune, Inc. (NASDAQ:ALT) to report earnings on May, 2. They expect $-0.50 earnings per share, down 66.67 % or $0.20 from last year’s $-0.3 per share. After $-0.12 actual earnings per share reported by Altimmune, Inc. for the previous quarter, Wall Street now forecasts 316.67 % negative EPS growth.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $12.82 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.

Altimmune, Inc. (NASDAQ:ALT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: